Robust immune evasion technology to enable persistence of allogeneic cell therapies
- Overcoming host rejection is critical for the success of allogeneic cell therapies
- Common approaches in the field to mitigate rejection will be discussed
- GentiBio’s proprietary immune evasion engineering enables durable persistence of allogeneic cells in preclinical models